Vaccines provide the most cost effective defense against pathogens. Although vaccines have been designed for a number of viral diseases, a vaccine against HIV-1 still remains elusive. In contrast while there are excellent influenza vaccines, these need to be changed every few years because of antigenic drift and shift The recent discovery of a large number of broadly neutralizing antibodies (bNAbs) and structural characterization of the conserved epitopes targeted by them presents an opportunity for structure based HIV-1 and influenza A vaccine design. We discuss strategies to design immunogens either targeting a particular antigenic region or focusing on native structure stabilization. This article is part of a Special Issue entitled: Rece...
Proteins are fundamental components in biological systems and crucial for a variety of biological fu...
Two of the principal challenges facing vaccine design today are how to generate protective antibody ...
Two of the principal challenges facing vaccine design today are how to generate protective antibody ...
Vaccines provide the most cost effective defense against pathogens. Although vaccines have been desi...
Many efforts have been made in the worldwide quest for a prophylactic HIV vaccine to end the AIDS pa...
Neutralizing antibodies can protect from infection by immunodeficiency viruses. However, the inducti...
A current strategy for the design of neutralizing antibody-based vaccines to prevent HIV-1 transmiss...
The ability to elicit broadly neutralizing antibody responses against HIV-1 is a crucial goal for a ...
The ability to elicit broadly neutralizing antibody responses against HIV-1 is a crucial goal for a ...
Vaccines have been one of the most successful interventions in global health. However, traditional v...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
The extraordinary variability of HIV-1 poses a major obstacle to vaccine development. The effectiven...
Over 30 years after the emergence of HIV-1, there is no effective vaccine, and AIDS remains an impor...
Introduction: The development of a human immunodeficiency virus 1 (HIV-1) vaccine remains a formidab...
Antigenic variation and viral evolution have thwarted traditional influenza vaccination strategies. ...
Proteins are fundamental components in biological systems and crucial for a variety of biological fu...
Two of the principal challenges facing vaccine design today are how to generate protective antibody ...
Two of the principal challenges facing vaccine design today are how to generate protective antibody ...
Vaccines provide the most cost effective defense against pathogens. Although vaccines have been desi...
Many efforts have been made in the worldwide quest for a prophylactic HIV vaccine to end the AIDS pa...
Neutralizing antibodies can protect from infection by immunodeficiency viruses. However, the inducti...
A current strategy for the design of neutralizing antibody-based vaccines to prevent HIV-1 transmiss...
The ability to elicit broadly neutralizing antibody responses against HIV-1 is a crucial goal for a ...
The ability to elicit broadly neutralizing antibody responses against HIV-1 is a crucial goal for a ...
Vaccines have been one of the most successful interventions in global health. However, traditional v...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
The extraordinary variability of HIV-1 poses a major obstacle to vaccine development. The effectiven...
Over 30 years after the emergence of HIV-1, there is no effective vaccine, and AIDS remains an impor...
Introduction: The development of a human immunodeficiency virus 1 (HIV-1) vaccine remains a formidab...
Antigenic variation and viral evolution have thwarted traditional influenza vaccination strategies. ...
Proteins are fundamental components in biological systems and crucial for a variety of biological fu...
Two of the principal challenges facing vaccine design today are how to generate protective antibody ...
Two of the principal challenges facing vaccine design today are how to generate protective antibody ...